摘要
目的:研究维拉帕米联用仙茅苷之后,维拉帕米和仙茅苷在大鼠体内可能发生的药物相互作用。方法:24只雄性SD大鼠,随机分为单药组和联用药组,单药组灌胃仙茅苷20 mg·kg^(-1),联用药组灌胃维拉帕米和仙茅苷,其给药剂量分别为10 mg·kg^(-1)和20 mg·kg^(-1)。在不同时间点取血,采用LC-MS测定仙茅苷的的血药浓度,计算并比较仙茅苷的药代动力学参数。结果:与单药组相比,联用药组仙茅苷药代动力学参数发生明显变化,其中仙茅苷最大血药浓度从189.13ng·m L^(-1)增加到277.53 ng·m L^(-1),血浆曲线下面积从949.18 ng·h·m L^(-1)增加到1728.08 ng·h·m L^(-1)。结论:维拉帕米联合仙茅苷用药之后,维拉帕米能明显增强仙茅苷在大鼠体内的血药浓度。
Objective： To investigate potential interaction between verapamil and curculigoside. Methods： Twenty-four rats were randomized to two groups（twelve rats in each group）, including the curculigoside-only group（A） and the curculigoide and verapamil group（B）. Animals in group A were administered oral curculigoside at 20 mg·kg^-1; and animals in group B were administered oral curculigoside（20 mg·kg^-1）and verapamil（10 mg·kg^-1）. Blood samples were collected at different time points after drug administration,and the plasma concentrations of curculigoside were determined using LC-MS. Finally the pharmacokinetic profiles of curculigoside were calculated and compared. Results： The results indicated that verapamil could significantly change the pharmacokinetic profiles of curculigoside in rats. Verapamil could significantly increase the peak plasma concentration（from 189.13 ng·m L^-1to 277.53 ng·m L^-1） and AUC0-t（from 949.18 ng·h·m L^-1to 1728.08 ng·h·m L^-1） of curculigoside. Conclusion： The results indicatedthat verapamil could significantly increase the plasma concentration of curculigoside when verapami and curculigside were concomitantly administered.
出处
《药学与临床研究》
2017年第1期9-12,共4页
Pharmaceutical and Clinical Research
